Effect of Feiyiliu Mixture on Prognosis of Patients with Middle and Advanced Squamous Cell Carcinoma of Lung
10.13422/j.cnki.syfjx.20200131
- VernacularTitle:肺抑瘤合剂对中、晚期肺鳞状细胞癌预后的影响
- Author:
Xian-tao LIU
1
;
Xin ZHENG
2
Author Information
1. Affiliated Hospital of Shandong University of Traditional Chinese Medicine(TCM), Ji'nan250011, China
2. Shandong University of TCM, Ji'nan250014, China
- Publication Type:Research Article
- Keywords:
non-small cell lung cancer;
squamous cell carcinoma;
Feiyiliu mixture;
progressive survival;
survival rate;
quality of life;
tumor markers;
cytokines
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2020;26(8):118-123
- CountryChina
- Language:Chinese
-
Abstract:
Objective::To discuss the effect of Feiyiliu mixture as an adjuvant method for chemotherapy and immune support on progression-free survival (PFS) and survival rate of patients with Ⅲb and Ⅳ stage squamous cell carcinoma of lung (SQCC), and to investigate its intervention effect on tumor markers and cytokines in peripheral blood. Method::One hundred and thirty-two patients were randomly divided into control group (66 cases) and observation group (66 cases) by random number table. Patients in control group received programme of gemcitabine hydrochloride combined with cisplatin (alternative paclitaxel combined with cisplatin) and they also got thymopolypeptides for injection, while the patients in observation group received Feiyiliu mixture, with a treatment course of 4 cycles in both groups. PFS and 12 months' survival rate were recorded during follow-up. Scores of European quality of life collaboration cancer core scale (EORTC QLQ-C30) were graded before and after treatment. Levels of CD3+, CD4+, CD8+, CD4+ /CD8+, cytokeratin 19 fragment 21-1 (CYFRA21-1), squamous cell carcinoma antigen (SCC), carbohydrate antigen 125 (CA125), vascular endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2) and MMP-9 were detected, and size of solid tumor was evaluated before and after treatment. Result::Clinical remission rate of solid tumor was (35/66)53.03% in observation group, higher than(23/66) 34.85% in control group (χ2=4.286, P<0.05). PFS in observation group was 9.8 months (95% CI, 4.58-22.37), more than 5.7 months in control group (95% CI, 4.69-20.41) (P<0.05). 12 months’ survival rate was 45.45% (30/36) in observation group, more than 27.27% (18/48) in control group (χ2=4.714, P<0.05). Scores of physical function, social function and overall quality of life in observation group were higher than those in control group (P<0.01), and scores of fatigue, nausea and vomiting, shortness of breath, loss of appetite, constipation and diarrhea were lower than those in control group (P<0.01). Levels of CD3+, CD4+ and CD4+ /CD8+ in observation group were higher than those in control group (P<0.05), while levels of CD8+, CYFRA21-1, SCC, CA125, VEGF, MMP-2 and MMP-9 were lower than those in control group (P<0.01). Conclusion::Adjuvant Feiyiliu mixture combined with chemotherapy and immune support can prolong PFS, improve survival rate, stabilize immune function, improve quality of life, inhibit the expression of cytokines such as CYFRA21-1 and vascular endothelial growth factor, and improve prognosis for patients with Ⅲb and Ⅳ stage SQCC. Therefore, it is worth further study and use
